GLP-1 Market Top Players - AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone produced in the gastrointestinal tract, which plays a vital role in regulating blood glucose levels and controlling appetite. GLP-1 receptor agonists are pharmaceutical agents designed to stimulate the GLP-1 receptor, resulting in a range of therapeutic effects, including enhanced insulin secretion from pancreatic beta cells in response to elevated glucose levels, suppression of glucagon secretion, delayed gastric emptying, and improved glucose utilization in peripheral tissues. These actions make GLP-1 receptor agonists highly effective for managing type 2 diabetes, as they help lower blood glucose levels and promote weight loss, which is a significant benefit for many individuals with diabetes. Additionally, certain GLP-1 receptor agonists have been approved for the treatment of obesity due to their appetite-suppressing and weight-reducing properties.

The GLP-1 receptor agonist market includes a variety of approved and investigational treatments, such as short-acting agents like exenatide and lixisenatide, long-acting formulations like semaglutide, dulaglutide, and liraglutide, as well as oral options like oral semaglutide (Rybelsus).

Furthermore, dual and tri-agonist therapies, such as tirzepatide, which target multiple receptors, are also being explored. The rising prevalence of diabetes and obesity, combined with the established efficacy and safety profiles of GLP-1 receptor agonists, has significantly driven market growth. As ongoing pharmaceutical advancements continue to expand the GLP-1 receptor agonist portfolio, the market is expected to sustain its growth trajectory in the coming years.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics:
Drivers:
The escalating global prevalence of type 2 diabetes and obesity is a principal driver of the GLP-1 receptor agonist market's growth. According to a study published in the Journal of the American Medical Association, the incidence of diabetes increased from 3% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020. GLP-1 receptor agonists have demonstrated significant efficacy in lowering blood glucose levels, reducing HbA1c, and promoting substantial weight loss. Recent regulatory approvals, such as semaglutide (Wegovy) for the treatment of obesity in addition to diabetes, have expanded the patient base, further accelerating market growth. Improved insurance coverage and growing affordability are enhancing patient access to these therapies. Additionally, ongoing pharmaceutical innovations, including the development of oral formulations and once-weekly injectable options, are improving patient convenience and treatment adherence, addressing existing gaps in healthcare.

Challenges:
Despite their proven effectiveness, GLP-1 receptor agonists face challenges related to patient adherence, largely due to gastrointestinal side effects such as nausea and vomiting, which can hinder sustained use. The need for subcutaneous injections also presents a challenge, although oral formulations like semaglutide are gaining traction. While long-acting versions with once-weekly dosing have been developed, there remains demand for even less frequent administration. Furthermore, the high cost of treatment and limited insurance coverage, particularly in emerging markets, continue to present substantial barriers to patient access, underscoring the need for more affordable solutions.

Regional Trends:
The Asia-Pacific (APAC) region is rapidly emerging as a key market for GLP-1 receptor agonists, with countries such as China, Japan, and India leading this growth. This expansion is driven by an evolving healthcare infrastructure, a large patient population, and significant unmet clinical needs for effective diabetes and obesity treatments. The rising prevalence of type 2 diabetes and obesity in the APAC region is further fueling demand for GLP-1 therapies. Major pharmaceutical companies are focusing their efforts on developing innovative GLP-1 receptor agonist solutions to meet the growing healthcare demands of this region.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.